Tag:
Amplify
Latest Headlines
Latest Headlines
Off-label doses of Medtronic bone product risky, study shows
A Medtronic ( $MDT ) bone-stimulation product recently rejected by the FDA might increase the risk of cancer, newly released study data show. Because the product, Amplify, is a higher-dose formulation
FDA says no to Medtronic's Amplify
The FDA has rejected Medtronic's ( $MDT ) Amplify, a spine device that was linked to higher cancer malignancy than alternative procedures for degenerative disc disease patients. The company had
Close vote at Amplify panel meeting
GAITHERSBURG, MD -- An expert FDA panel has cast a narrow vote on Medtronic's ( NYSE: MDT ) Amplify matrix device, which uses a bone morphogenic protein to stimulate bone growth in patients with
Increased cancer risk found with Medtronic's Amplify spine stabilizer
Although two-year studies looked promising for Amplify, the five year studies are worrisome. Medtronic's spine stabilizing device has been linked to higher cancer malignancy than alternative
